The University of Pennsylvania and the University of Arkansas for Medical Sciences are conducting a research study of an investigational medicine for individuals between the ages of 18 and 80 who have idiopathic multicentric Castleman disease (iMCD) and are unable to benefit from anti-IL-6 therapies. Anti-IL-6 therapies are siltuximab (Sylvant) and tocilizumab (Actemra). If you are an iMCD patient who is currently experiencing disease activity and are either unable to tolerate anti-IL-6 therapy, or your disease does not respond to anti-IL-6 therapy, please contact the CSTL for additional information on this study. Participation in this study is entirely voluntary. 

Eligible participant will receive, at no cost, study related:

• Medical procedures

• Laboratory assessment

• Investigational medication

• Reimbursement for study travel may be available

More information about this trial can also be found at: https://clinicaltrials.gov/ct2/show/NCT03933904.